VivoSeq
Ophthalmology

Retinopathy

38

Pipeline Programs↗

7

Active Trials↗

16

Companies Involved↗

Retinopathy is a moderately active landscape with 38 programs across 16 companies. The most active players are EMD Serono, Sanofi, Regeneron. 6 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

0/100

Mech. Concentration

13/100

Completion Rate

81/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

EMD Serono logo

EMD Serono

1 program

Phase 1Sanofi logo

Sanofi

1 program

Phase 1Regeneron logo

Regeneron

2 programs

Phase 2A

Ascidian Therapeutics, Inc

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

81%

Small molecule

34 of 42 classified programs — the dominant modality here.

19%ALL OTHERSMonoclonal antibody512%Protein / enzyme25%Cell therapy12%

Small molecule leads; the ring shows all 42 classified programs, each share of the total. Modality classified for 100% of 44 pipeline programs.

Analysis

Trial Status

54

clinical trials

Completed29 · 54%
Unknown status11 · 20%
Terminated4 · 7%
Recruiting4 · 7%
Withdrawn3 · 6%
Active, not recruiting2 · 4%
Other1 · 2%

Clinical Trials

Trial Activity

54 trials

Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Recruiting·JJaeb Center for Health Research·Phase 3·NCT05844982·600 enrolled
Steroid Eye Drops in Chronic Central Serous Chorioretinopathy
Recruiting·RRadboud University Medical Center·Phase 3·NCT05633576·40 enrolled
Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy
Recruiting·HHelse Stavanger HF·N/A·NCT05589974·50 enrolled
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
Recruiting·AAscidian Therapeutics, Inc·Phase 1/2·NCT06467344·15 enrolled
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
Active, not recruiting·UUniversity of California, Davis·Phase 1·NCT01736059·15 enrolled
Oral Metformin for Treatment of ABCA4 Retinopathy
Active, not recruiting·National Eye Institute (NEI)·Preclinical·NCT04545736·55 enrolled
Evaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy
Not yet recruiting·—·Phase 2/3·NCT06809751·48 enrolled
Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
Completed·VVitreous -Retina- Macula Consultants of New York·Phase 1·NCT00403325·9 enrolled
Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy
Completed·SShin Kong Wu Ho-Su Memorial Hospital·N/A·NCT01019668·24 enrolled
Safety and Efficacy of Propranolol Eye Drops in Treating Retinopathy of Premature
Completed·MMeyer Children's Hospital IRCCS·Phase 2·NCT02014454·23 enrolled
Short-Term Oral Mifepristone for Central Serous Chorioretinopathy
Completed·—·Phase 2·NCT02354170·16 enrolled
Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC)
Completed·MManhattan Eye, Ear & Throat Hospital·Phase 2·NCT00211445·11 enrolled
A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole
Completed·MManhattan Eye, Ear & Throat Hospital·Phase 2·NCT00211393·5 enrolled
Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)
Completed·JJohann Wolfgang Goethe University Hospital·N/A·NCT00802906·12 enrolled
Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
Completed·GGreater Houston Retina Research·Phase 2·NCT02222610·40 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)